0.745
price down icon0.49%   -0.0045
 
loading
Schlusskurs vom Vortag:
$0.7495
Offen:
$0.7569
24-Stunden-Volumen:
718.51K
Relative Volume:
0.36
Marktkapitalisierung:
$138.50M
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-0.5103
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
+6.65%
1M Leistung:
-0.82%
6M Leistung:
-26.88%
1J Leistung:
-46.73%
1-Tages-Spanne:
Value
$0.72
$0.78
1-Wochen-Bereich:
Value
$0.6728
$0.8297
52-Wochen-Spanne:
Value
$0.432
$1.5195

Nektar Therapeutics Stock (NKTR) Company Profile

Name
Firmenname
Nektar Therapeutics
Name
Telefon
(415) 482-5300
Name
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
Mitarbeiter
61
Name
Twitter
@nektarnews
Name
Nächster Verdiensttermin
2025-03-12
Name
Neueste SEC-Einreichungen
Name
NKTR's Discussions on Twitter

Vergleichen Sie NKTR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NKTR
Nektar Therapeutics
0.7442 125.53M 90.12M -276.06M -193.47M -1.46
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.24 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.93 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.95 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
485.38 65.13B 14.09B 4.50B 2.96B 39.28

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-11 Hochstufung Jefferies Hold → Buy
2025-03-14 Hochstufung Oppenheimer Perform → Outperform
2025-01-08 Eingeleitet B. Riley Securities Buy
2024-12-10 Eingeleitet H.C. Wainwright Buy
2024-11-04 Eingeleitet Piper Sandler Overweight
2024-09-30 Fortgesetzt BTIG Research Buy
2024-06-28 Eingeleitet Rodman & Renshaw Buy
2023-11-20 Fortgesetzt JP Morgan Underweight
2023-11-09 Hochstufung TD Cowen Market Perform → Outperform
2023-05-10 Hochstufung Jefferies Underperform → Hold
2023-02-24 Herabstufung Jefferies Hold → Underperform
2022-08-08 Herabstufung JP Morgan Neutral → Underweight
2022-05-31 Fortgesetzt Jefferies Hold
2022-04-18 Herabstufung Goldman Neutral → Sell
2022-03-15 Herabstufung Cowen Outperform → Market Perform
2022-03-15 Herabstufung Mizuho Buy → Neutral
2022-03-14 Herabstufung BTIG Research Buy → Neutral
2022-03-14 Herabstufung BofA Securities Neutral → Underperform
2022-03-14 Herabstufung Stifel Buy → Hold
2022-03-14 Herabstufung William Blair Outperform → Mkt Perform
2022-03-09 Hochstufung Oppenheimer Perform → Outperform
2021-11-08 Hochstufung The Benchmark Company Hold → Buy
2021-09-10 Eingeleitet BofA Securities Neutral
2021-06-28 Hochstufung Stifel Hold → Buy
2021-05-18 Fortgesetzt Goldman Neutral
2021-02-22 Herabstufung The Benchmark Company Buy → Hold
2021-01-06 Eingeleitet Stifel Hold
2020-09-14 Eingeleitet JP Morgan Neutral
2020-06-10 Herabstufung CFRA Hold → Sell
2020-05-12 Bestätigt H.C. Wainwright Neutral
2020-04-22 Eingeleitet The Benchmark Company Buy
2020-03-30 Hochstufung Goldman Sell → Neutral
2020-03-04 Eingeleitet Barclays Overweight
2020-02-03 Hochstufung Mizuho Neutral → Buy
2019-10-24 Eingeleitet Oppenheimer Perform
2019-10-08 Herabstufung Goldman Buy → Sell
2019-08-09 Herabstufung JP Morgan Overweight → Neutral
2019-08-09 Herabstufung Jefferies Buy → Hold
2019-08-09 Herabstufung Mizuho Buy → Neutral
2019-03-15 Eingeleitet SVB Leerink Mkt Perform
2018-12-13 Eingeleitet Goldman Buy
2018-06-11 Herabstufung H.C. Wainwright Buy → Neutral
2018-06-04 Bestätigt H.C. Wainwright Buy
2018-04-20 Eingeleitet Seaport Global Securities Buy
2018-04-13 Fortgesetzt Piper Jaffray Overweight
2018-04-06 Bestätigt Mizuho Buy
2018-04-02 Fortgesetzt H.C. Wainwright Buy
Alle ansehen

Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten

pulisher
May 30, 2025

Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 30, 2025
pulisher
May 29, 2025

Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 29, 2025
pulisher
May 29, 2025

D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 29, 2025
pulisher
May 28, 2025

Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com

May 28, 2025
pulisher
May 28, 2025

BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 28, 2025
pulisher
May 28, 2025

Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks

May 28, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com

May 26, 2025
pulisher
May 26, 2025

Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail

May 26, 2025
pulisher
May 23, 2025

Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st

May 23, 2025
pulisher
May 22, 2025

Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World

May 22, 2025
pulisher
May 20, 2025

Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq

May 20, 2025
pulisher
May 16, 2025

Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN

May 16, 2025
pulisher
May 16, 2025

Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World

May 16, 2025
pulisher
May 16, 2025

What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World

May 16, 2025
pulisher
May 15, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 15, 2025
pulisher
May 15, 2025

Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World

May 15, 2025
pulisher
May 14, 2025

GSK’s liver asset play grows group of $1B upfront deals - biocentury.com

May 14, 2025
pulisher
May 14, 2025

Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN

May 13, 2025
pulisher
May 13, 2025

Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance

May 13, 2025
pulisher
May 13, 2025

Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World

May 13, 2025
pulisher
May 12, 2025

Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks

May 12, 2025
pulisher
May 12, 2025

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 12, 2025
pulisher
May 12, 2025

Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World

May 12, 2025
pulisher
May 12, 2025

Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com

May 12, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 11, 2025
pulisher
May 11, 2025

Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks

May 09, 2025
pulisher
May 09, 2025

BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India

May 09, 2025
pulisher
May 09, 2025

Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st

May 09, 2025
pulisher
May 09, 2025

NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView

May 09, 2025
pulisher
May 09, 2025

BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 09, 2025
pulisher
May 09, 2025

Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Nektar misses Q1 2025 forecasts amid clinical progress - Investing.com

May 09, 2025
pulisher
May 09, 2025

Nektar: Q1 Earnings Snapshot - The Washington Post

May 09, 2025
pulisher
May 08, 2025

Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Q1 2025 Earnings: EPS Loss of $0.24 Misses E - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar (NKTR) Reports Revenue Miss and Announces Key Study Timel - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics (NKTR) Misses Q1 EPS by 8c - StreetInsider

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Reports First Quarter 2025 Financial Results | NKTR Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Nektar Therapeutics Q1 Loss Increases, Misses Estimates - Nasdaq

May 08, 2025

Finanzdaten der Nektar Therapeutics-Aktie (NKTR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Nektar Therapeutics-Aktie (NKTR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Wilson Mark Andrew
Chief Legal Officer
May 19 '25
Sale
0.67
9,996
6,697
314,296
ROBIN HOWARD W
President & CEO
May 19 '25
Sale
0.67
23,208
15,549
1,063,693
$1.16
price up icon 0.87%
$31.13
price down icon 0.19%
$576.61
price down icon 1.37%
$303.77
price down icon 0.76%
$4.5807
price down icon 0.41%
$487.86
price up icon 0.56%
Kapitalisierung:     |  Volumen (24h):